Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Operating Expenses (2019 - 2023)

Historic Operating Expenses for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to $50.6 million.

  • ADC Therapeutics' Operating Expenses rose 16375.28% to $50.6 million in Q3 2023 from the same period last year, while for Dec 2023 it was $109.5 million, marking a year-over-year increase of 16577.87%. This contributed to the annual value of $4.8 billion for FY2022, which is 730.12% up from last year.
  • Latest data reveals that ADC Therapeutics reported Operating Expenses of $50.6 million as of Q3 2023, which was up 16375.28% from $58.9 million recorded in Q2 2023.
  • Over the past 5 years, ADC Therapeutics' Operating Expenses peaked at $4.6 billion during Q2 2022, and registered a low of -$86.9 million during Q1 2022.
  • Its 5-year average for Operating Expenses is $468.2 million, with a median of -$35732.0 in 2019.
  • Over the last 5 years, ADC Therapeutics' Operating Expenses had its largest YoY gain of 18355385106.3% in 2022, and its largest YoY loss of 177915935.05% in 2022.
  • Quarter analysis of 5 years shows ADC Therapeutics' Operating Expenses stood at -$35732.0 in 2019, then tumbled by 146625.62% to -$52.4 million in 2020, then soared by 99.85% to -$79791.0 in 2021, then fell by 0.93% to -$80536.0 in 2022, then soared by 62981.2% to $50.6 million in 2023.
  • Its Operating Expenses stands at $50.6 million for Q3 2023, versus $58.9 million for Q2 2023 and $3.7 billion for Q1 2023.